Inhibitor of vascular endothelial growth factor receptor (VEGFR). Used for patients with advanced RCC who have not received prior systemic therapy.Induces cellular senescence triggering Nrf2/p53/plasminogen activator inhibitor (PAI) axis. Here, KDR is linked to renal cell carcinoma.